Aquestive Therapeutics, Inc. AQST Royalty Obligations, Gross
Royalty Obligations, Gross at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:RoyaltyObligationsGross.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s royalty obligations, gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s royalty obligations, gross?
- Aquestive Therapeutics, Inc. (AQST) reported royalty obligations, gross of $51.89M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s royalty obligations, gross?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s royalty obligations, gross has grown at a -4.5% compound annual growth rate (CAGR), from $56.93M to $51.89M.
- What does royalty obligations, gross mean?
- This represents the total undiscounted royalty obligations owed to third parties before any accounting adjustments or present value discounting. It provides a comprehensive view of the total contractual liability related to intellectual property and licensing agreements. Investors use this to understand the full magnitude of future revenue-sharing commitments.